Facebook
Twitter
LinkedIn
Forward
Cognitive Impairment in Huntington Disease
Program Introduction
An updated review of pathophysiology, emerging treatments, and supportive care strategies in the cognitive dimension of Huntington disease.
Learning Objectives
After completing this educational activity, you should be able to:
- Review the multisystem nature of Huntington disease
- Explore the clinical phenomenology of mild cognitive impairment in Huntington disease, including its impact on executive functioning
- Identify the possible role of NMDA receptors in the pathogenesis and treatment of Huntington disease
- Examine the current and emerging treatment landscape for nonmotor aspects of Huntington disease
- Examine the impact of multidisciplinary management on HD
Target Audience
Neurologists, psychiatrists, and movement disorder specialists
Program Description
Join Susan Perlman, MD and Christopher Ross, MD, PhD for an in-depth examination of cognitive impairment in Huntington disease. Through this presentation, participants can gain a better appreciation for the non-motor deficits that detract from patient-related quality of life in Huntington disease, describe the neuropathological changes driving disease development, and differentiate between early-stage and late-stage cognitive deficits. In the second half of the presentation, viewers can review key developments in the treatment landscape for non-motor aspects of Huntington disease and evaluate data quantifying the impact of multidisciplinary management approaches. Although Huntington disease lacks a cure and disease-modifying interventions, supportive care strategies can delay the onset of disabilities and alleviate some of the emotional burden associated with non-motor symptoms.
Support Statement
Supported by an educational grant from Sage Therapeutics, Inc.
Learning Objective
After completing this educational activity, you should be able to:
- Review the multisystem nature of Huntington disease
- Explore the clinical phenomenology of mild cognitive impairment in Huntington disease, including its impact on executive functioning
- Identify the possible role of NMDA receptors in the pathogenesis and treatment of Huntington disease
- Examine the current and emerging treatment landscape for nonmotor aspects of Huntington disease
- Examine the impact of multidisciplinary management on HD
Release, Review, and Expiration Dates
This CME activity was published in April 2023 and is eligible for AMA PRA Category 1 Credit™ through April 30, 2024.
Statement of Need and Purpose
Huntington’s disease has FDA approved treatments for its disease components related to motor movements, however nothing except symptom management exists for the cognitive aspects of the disease. There is a need for clinicians to understand more about the disease state as it pertains to the neurobiological pathology of Huntington’s and how it deteriorates and individuals executive functioning. The role of the NMDA receptor and its modulation is being researched as a meaningful therapeutic target for cognitive impairment associated with HD. There are other modalities and therapeutics in discovery that clinicians should understand as the disease becomes more well-known. Treating this disease requires an effort to address the body as well as the mind. A multi-disciplinary approach, both in diagnostic acuity and therapeutic management, is critical to ensure patients are receiving the best care available.
Unlabeled and Investigational Usage
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.
Review Process
The faculty members agreed to provide a balanced and evidence-based presentation and discussed the topics and CME objectives during the planning sessions. The faculty’s submitted content was validated by CME Institute staff, and the activity was evaluated for accuracy, use of evidence, and fair balance by the Chair and a peer reviewer who is without conflict of interest.
The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter
© Copyright 2023 Physicians Postgraduate Press, Inc.
Faculty Affiliation
Susan Perlman, MD |
Christopher Ross, MD, PhD |
Financial Disclosure
The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:
Dr. Ross has received consulting fees fromHuntington Study Group, he has received grant/research support from Prilenia, T3D, he has received honoraria from Movement Disorder Society and he is on the advisory boards for Prilenia, Annexon, Remix.
Dr. Perlman has no financial disclosures.
None of the other planners, reviewers, and CME Institute staff for this educational activity have relevant financial relationships with ineligible companies to disclose. All relevant financial relationships have been mitigated.
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation